|
|
Volumn 417, Issue 6889, 2002, Pages 584-586
|
|
Magic bullets hit the target
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOTECHNOLOGY;
DRUG PRODUCTS;
DRUGS;
ANTIBODIES;
ABCIXIMAB;
ALEMTUZUMAB;
GEMTUZUMAB OZOGAMICIN;
IBRITUMOMAB TIUXETAN;
INFLIXIMAB;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
MONOCLONAL ANTIBODY;
OKT 3;
PALIVIZUMAB;
RITUXIMAB;
TRASTUZUMAB;
HYBRID PROTEIN;
BIOTECHNOLOGY;
DRUG DEVELOPMENT;
CLINICAL RESEARCH;
DRUG APPROVAL;
DRUG COST;
PRIORITY JOURNAL;
SHORT SURVEY;
ANIMAL;
ANTIBODY SPECIFICITY;
ARTICLE;
AWARDS AND PRIZES;
BIOSYNTHESIS;
BIOTECHNOLOGY;
CHEMICAL STRUCTURE;
CHEMISTRY;
DRUG INDUSTRY;
HUMAN;
IMMUNOLOGY;
METHODOLOGY;
MOUSE;
NEOPLASM;
PROTEIN CONFORMATION;
PROTEIN ENGINEERING;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIBODY SPECIFICITY;
BIOTECHNOLOGY;
DRUG INDUSTRY;
HUMANS;
MICE;
MODELS, MOLECULAR;
NEOPLASMS;
NOBEL PRIZE;
PROTEIN CONFORMATION;
PROTEIN ENGINEERING;
RECOMBINANT FUSION PROTEINS;
|
|
EID: 0037030412
PISSN: 00280836
EISSN: None
Source Type: Journal
DOI: 10.1038/417584a Document Type: Short Survey |
|
Times cited : (122)
|
|
References (12)
|
